Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Awakn Life Sciences Corp. (AWKN) has announced a licensing partnership with Revitalist Lifestyle and Wellness (CALM)
  • The agreement empowers Revitalist to treat clients with Awakn’s proprietary ketamine-assisted therapy for the treatment of AUD
  • Awakn will provide access to its proprietary therapeutics and training to Revitalist practitioners, while Revitalist will pay Awakn an annual fee and a revenue share per treatment
  • Awakn Life Sciences Corp. is a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat substance and behavioural addictions
  • Revitalist Lifestyle and Wellness Ltd. was up 7.14 per cent, trading at C$0.075 at 12:02 ET

Awakn Life Sciences Corp. (AWKN) has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness (CALM).

Revitalist is one of the largest publicly-listed, ketamine-focused clinic operations in the United States.

The agreement empowers Revitalist to treat clients with Awakn’s proprietary ketamine-assisted therapy for the treatment of AUD.

Awakn’s proprietary treatment was developed and validated in a Phase II a/b trial. The results of the trial were published in January 2022 in the American Journal of Psychiatry.

The trial delivered 86 per cent abstinence over the six-month post-treatment versus 2 per cent pre-trial. The current standard of care has an approximate 25 per cent abstinence rate over the same timeframe.

Under the terms of the licence agreement, Awakn will provide access to its proprietary therapeutics and training to Revitalist practitioners. At the same time, Revitalist will pay Awakn an annual fee and a revenue share per treatment.

Awakn aims to improve performance of this industry by providing clinic operators with access to an efficient and effective treatment option under licence.

“Our partnership agreement with Revitalist adds an additional revenue stream for Awakn in our licensing partnerships’ business, and importantly brings us into a new, and key territory – the United States,” stated Anthony Tennyson, Awakn CEO.

“Now, for the first time in the United States, these individuals are able to access this promising treatment to help them remain in remission of their addictive behaviours,” noted Kathryn Walker, Revitalist CEO.

Awakn Life Sciences Corp. is a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat substance and behavioural addictions.

Revitalist Lifestyle and Wellness Ltd. was up 7.14 per cent, trading at C$0.075 at 12:02 ET.


More From The Market Herald

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.

" Origin Therapeutics’ (CSE:ORIG) Xpira Pharmaceuticals receive FDA approval for psilocybin

Origin Therapeutics’ (ORIG) company, Xpira Pharmaceuticals, receives FDA approval for psilocybin for a trial IND application.
Numinus Wellness - Founder & CEO, Payton Nuquvest

" Numinus (TSX:NUMI) expands ketamine therapy

Numinus Wellness (NUMI) announced the opening of a new clinic in Montreal that will replace an existing downtown clinic.

" Optimi Health (CSE:OPTI), ATMA Journey Centres to proceed with Phase I natural psilocybin and MDMA clinical trial application to Health Canada

Optimi Health (OPTI) has confirmed its intent to proceed with a Phase I clinical trial application (CTA).